Objective-Clusterin is induced in vascular smooth muscle cells (VSMCs) during atherosclerosis and injury-induced neointimal hyperplasia. However, its functional roles in VSMCs and endothelial cells remain controversial and elusive. This study was undertaken to clarify the role of clusterin in neointimal hyperplasia and elucidate its mechanism of action. Methods and Results-Adenovirus-mediated overexpression of clusterin (Ad-Clu) repressed TNF-␣-stimulated expression of MCP-1, fractalkine, ICAM-1, VCAM-1, and MMP-9, leading to inhibition of VSMC migration. Both Ad-Clu and secreted clusterin suppressed VSMC proliferation by inhibiting DNA synthesis, but not by inducing apoptosis. Ad-Clu upregulated p53 and p21 cip1/waf1 but downregulated cyclins D and E, leading to suppression of pRb phosphorylation and subsequent induction of G1 arrest in VSMCs. Clusterin deficiency augmented VSMC proliferation in vitro and accelerated neointimal hyperplasia in vivo, but concomitantly impaired reendothelialization in wire-injured murine femoral arteries. Moreover, Ad-Clu significantly reduced neointimal thickening in balloon-injured rat carotid arteries. Clusterin also diminished TNF-␣-induced apoptosis of human umbilical vein endothelial cells and restored endothelial nitric oxide synthase expression suppressed by TNF-␣. Conclusion-These results suggest that upregulation of clusterin during vascular injury may be a protective response against, rather than a causative response to, the development of neointimal hyperplasia. (Arterioscler Thromb Vasc Biol. 2009;29:1558-1564.) 
T he excessive proliferation and migration of VSMCs from arterial media to intima are the major cause of neointimal hyperplasia, which contributes to the development and progression of vascular pathologies such as atherosclerosis, restenosis after angioplasty, and vein-graft failure. [1] [2] [3] [4] [5] Cytokines and growth factors such as TNF-␣ and PDGF participate in these processes. In such pathological conditions, VSMCs express several proinflammatory chemokines, cell adhesion molecules, and matrix degrading endopeptidases (MMPs), such as fractalkine, monocyte chemotatic protein (MCP-1), intercellular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and matrix metalloproteinase-9 (MMP-9). 6 -10 These molecules are the therapeutic targets for the prevention and treatment of atherosclerosis and postangioplasty restenosis. 11 Growth factors and cytokines stimulate VSMC proliferation through acceleration of cell cycle progression, which is tightly controlled by several cell cycle-regulatory proteins. 3, 5, 12 G0/G1 to S-phase transition is triggered by phosphorylation of a key cell cycle regulator, retinoblastoma protein (pRb), resulting in upregulation of genes required for DNA synthesis and cell cycle progression. 13 pRb phosphorylation is mediated by cyclin-cdk complex and thus its phosphorylation status is regulated by the expression levels of both cell cycle-stimulatory (ie, cyclins D, E, and A) and inhibitory proteins (ie, p53 and cdk inhibitors, p21 waf1/cip1 and p27 kip1 [hereafter termed p21 and p27]). p53 upregulates p21, and p21 inhibits cyclin-cdk complexes and subsequent pRB phosphorylation, leading to the G1 arrest.
Clusterin (Clu)/Apolipoprotein (Apo) J is a secreted heterodimeric glycoprotein, composed of ␣ and ␤ subunits. 14, 15 Clusterin is detected in the intima and media of aortas with atherosclerotic lesions but not in normal aorta, and induced during the progression of atherosclerosis and postangioplasty restenosis. 16 -20 Although these data suggest that clusterin plays a crucial role in atherosclerosis and restenosis, its role is still controversial. Some studies have suggested that clusterin protects against atherosclerosis through its antiinflammatory property. 16, 18, 19 There are also conflicting reports showing that clusterin stimulates or inhibits VSMC proliferation and migration. 20, 21 Additionally, endothelial dysfunction and impaired reendothelialization play an important role in the development of atherosclerosis and restenosis. [22] [23] [24] However, little study has been performed to clarify the role of clusterin in endothelial cell (EC) apoptosis or dysfunction. Therefore, it is still unclear whether clusterin promotes or prevents neointimal hyperplasia, and its detailed molecular mechanism of action remains to be elucidated.
Here, we demonstrate that clusterin deficiency exacerbates neointimal hyperplasia and impairs reendothelialization in wire-injured femoral arteries. We also elucidate the molecular mechanism by which clusterin suppresses VSMC proliferation and exerts cytoprotective effects on ECs. Therefore, our data suggest that clusterin plays a critical role in protection against restenosis after vascular injury.
Materials and Methods

Animals
Four-week-old male Sprague-Dawley (SD) rats (Hyochang, Daegu, Korea) were used in the experiments. To generate both WT and Clu KO mice with the genetic background of C57BL/6J, clusterin deficient mice originally generated using a Swiss black genetic background 25 were backcrossed to C57BL/6J strains for at least 7 generations. All procedures complied with the institutional guidelines for animal research.
For expanded Materials and Methods, please see the supplemental materials (available online at http://atvb.ahajournals.org).
Results
Clusterin Inhibits VSMC Migration by Inhibiting TNF-␣/NF-B Signaling Pathway
To clarify the role of clusterin in the VSMC migration and proliferation, we used adenovirus expressing a secreted form of clusterin (Ad-Clu) or LacZ (Ad-LacZ). Clusterin expression was confirmed by Western blot analysis (supplemental Figure I) . To investigate the effect of clusterin on VSMC migration, woundhealing assay was performed in VSMCs infected with Ad-Clu or Ad-LacZ. Serum-stimulated migration of VSMCs was significantly inhibited by clusterin overexpression ( Figure 1A) .
To explore the molecular mechanism of antimigratory action of clusterin, we examined the expression of chemokines, cell adhesion molecules, and MMP-9, which play important roles in VSMC migration and proliferation. 6 -10 Semiquantitative RT-PCR analysis showed that Ad-Clu markedly decreased TNF-␣-stimulated mRNA expression of MCP-1, ICAM-1, VCAM-1, and MMP-9 in a multiplicity of infection (MOI)-dependent manner ( Figure 1B ). Protein levels of fractalkine and VCAM-1 were significantly diminished by Ad-Clu (supplemental Figure I) . Additionally, clusterin repressed the TNF-␣-stimulated promoter activity of MMP-9 ( Figure 1C ). Because all these molecules are upregulated by TNF-␣/NF-B signaling pathway and contribute to VSMC migration and proliferation, 6 -11 we examined whether clusterin could affect the TNF-␣-stimulated NF-B signaling. Clusterin inhibits VSMC migration through downregulation of chemokines, cell adhesion molecules, and MMP-9. A, Wound healing assay. VSMCs were infected with Ad-Clu or Ad-LacZ and serum starved for 24 hours. Cells were wounded by razor scraping and then incubated with serum for 24 hours. B, VSMCs infected with Ad-Clu or Ad-LacZ were serum starved for 24 hours and treated with TNF-␣ for 3 hours or 24 hours (MMP-9). Total RNA was isolated for semiquantitative RT-PCR analysis. C and D, Cos-1 cells infected with Ad-LacZ or Ad-Clu were transfected with MMP-9-pro-Luc (C) and pNF-B-Luc (D) and stimulated with TNF-␣ for 24 hours. *PϽ0.05 vs reporter alone, **PϽ0.05 vs TNF-␣ stimulation. Cells were harvested for luciferase and ␤-galactosidase assays. Luciferase activity was normalized to ␤-galactosidase activity and data are expressed as fold transactivation relative to the luciferase activity of the reporter alone. *PϽ0.005 vs reporter alone.
Clusterin repressed TNF-␣-induced transactivity of NF-B ( Figure 1D ), whereas it had little effect on Egr-1-, CREB-, and AP-1-dependent reporter activities (supplemental Figure  II ), suggesting its specificity for NF-B inhibition. These results suggest that clusterin inhibits VSMC migration by downregulating chemokines, cell adhesion molecules, and MMP-9, at least in part, through inhibition of NF-B activity.
Clusterin Reduces VSMC Proliferation by Inhibiting DNA Synthesis
To investigate the effect of clusterin on VSMC proliferation, WST-1 cell proliferation and trypan blue cell counting assays were performed. Serum treatment stimulated proliferation of quiescent VSMCs, and this serum-stimulated VSMC proliferation was significantly diminished by Ad-Clu but not by Ad-LacZ ( Figure 2A ). Trypan blue cell counting assay also showed that Ad-Clu reduced serum-stimulated increase in cell numbers ( Figure 2B ). Because WST-1 and cell counting assays reflect not only cell proliferation but also viability and cytotoxicity, BrdU incorporation assay was performed to investigate the effect of clusterin on the DNA synthesis. Similar to the results from WST-1 and cell counting assays, Ad-Clu strongly inhibited DNA synthesis induced by serum stimulation ( Figure 2C ).
To exclude the possibility that excessive secretion of clusterin by Ad-Clu may influence VSMC proliferation, the direct effect of secreted form of clusterin was examined. Incubation of VSMCs with conditioned medium containing secreted clusterin, but not control medium resulted in a strong inhibition of both serum-and PDGF-stimulated VSMC proliferation ( Figure 2D ). These observations suggest that both clusterin overexpression and secreted clusterin have an antiproliferative effect on VSMCs through inhibition of DNA synthesis.
Clusterin Induces G1 Phase Cell Cycle Arrest by Inhibiting pRb Phosphorylation
To further analyze which phase of cell cycle is controlled by clusterin and whether apoptosis is involved in antiproliferative effect of clusterin, we used a FACS cell cycle analysis. Serum stimulation of VSMCs synchronized in G0/G1 phase dramatically increased the percentage of cells in S phase ( Figure 3A ). Ad-Clu, but not Ad-LacZ, strongly reduced this serum-stimulated accumulation of cells in S phase and concomitantly increased cell numbers in G0/G1 phase, consistent with the result from Figure 2C . Notably, Ad-Clu did not induce any significant accumulation of cells in Sub G1 phase, indicating that apoptosis is not involved in the antiproliferative role of clusterin in VSMCs.
Next, we investigated whether clusterin affects the phosphorylation of pRb (ppRb) which is required for the cell cycle progression from G0/G1 to S phase. 12, 13 Phosphorylated pRb levels were dramatically increased from 6 to 24 hours after serum stimulation, whereas total pRb proteins were decreased ( Figure 3B ). This is probably because phosphorylated forms of pRb are subject to ubiquitination and degradation. Ad-Clu significantly diminished phosphorylated pRb and concomitantly increased total pRb in an MOI-dependent manner ( Figure 3C ). These results propose that clusterin suppresses VSMC proliferation through G1 phase arrest by inhibiting pRb phosphorylation.
Finally, we evaluated the effect of clusterin on the expression of cell cycle-regulatory proteins which regulate pRb phosphorylation status. The expression of cell cycle-promoting proteins (ie, cyclin D and cyclin E) was significantly diminished by Ad-Clu ( Figure 3D ). In contrast, clusterin concomitantly increased key cell cycle-inhibitory proteins including p53, phospho-p53 and p21, but not p27. Additionally, Ad-Clu increased p53 and p21 mRNA levels and stimulated the p53 and p21 gene promoters (supplemental Figure III) , indicating that clusterin regulates p53 and p21 expression at the transcriptional level. These results suggest that clusterin induces G1 phase cell cycle arrest by inhibiting pRb phosphorylation but not by inducing apoptosis, and that this effect is mediated through downregulation of cyclins D and E, and upregulation of p53-p21 pathway.
Clusterin Deficiency Augments VSMC Proliferation
To further confirm the antiproliferative property of endogenous clusterin, we examined the effect of clusterin deficiency on VSMC proliferation using VSMCs obtained from wildtype (WT) and clusterin homozygote knock-out (Clu KO) mice ( Figure 4A ). Consistent with the results using Ad-Clu (Figure 2 ), serum-stimulated proliferation of Clu KO VSMCs was significantly enhanced compared with that of WT VSMCs ( Figure 4B ). This increased proliferation of Clu KO VSMCs was reversed by infection with Ad-Clu, but not with Ad-LacZ ( Figure 4C ). Consistent with augmented proliferation of Clu KO VSMCs, p21, phospho-p53 and total pRb proteins were reduced, whereas phospho-pRb and cyclins D and E proteins were upregulated in Clu KO VSMCs ( Figure  4D ). These results suggest that endogenous clusterin is indispensable for the inhibition of VSMC proliferation.
Essential Role of Clusterin in Protection Against Neointimal Hyperplasia In Vivo
To evaluate the in vivo role of clusterin in neointimal hyperplasia, two vascular injury models (ie, wire-and cuff-injuries) were used in femoral arteries of WT and Clu KO mice. Based on the antiproliferative and antimigratory properties of clusterin, we assumed that neointima formation would be accelerated in Clu KO mice. Thus, we examined the femoral arteries 7 days earlier than usual (ie, 21 or 14 days after wire injury or cuff placement, respectively). At 21 days after wire injury, neointima formation was significantly developed in wire-injured arteries of WT mice, whereas there was no intimal thickening observed in the noninjured control femoral arteries of either WT or Clu KO mice ( Figure 5A and 5B) . Consistent with the result of augmented proliferation of Clu KO VSMCs (Figure 4) , neointimal hyperplasia in wire-injured Clu KO arteries was exacerbated compared with that of WT arteries. Clusterin was expressed in the neointimal region in wire-injured arteries of WT but not Clu KO mice, whereas it was not detectable in either noninjured WT or Clu KO arteries ( Figure 5C ), in agreement with a previous report. 26 Similarly, neointima formation was accelerated in cuff-injured femoral arteries of Clu KO mice compared with that of WT mice (supplemental Figure IV) .
Next, to examine whether overexpression of clusterin suppresses neointimal hyperplasia in vivo, Ad-GFP or Ad-Clu was infused into rat carotid arteries after balloon injury (BI). BIinduced neointima formation was prominent 14 days after BI and slightly pronounced at 28 days after BI. Ad-Clu but not Ad-GFP significantly reduced neointimal thickening at 28 days, as well as 14 days after BI, suggesting that clusterin suppresses, rather than just delays, neointimal hyperplasia (Figure 5D ). Clusterin overexpression was confirmed by immunohistochemistry (supplemental Figure V) . Collectively, these observations indicate that clusterin plays a crucial role in protection against neointimal hyperplasia in vivo.
Beneficial Effects of Clusterin on ECs
It has been reported that delayed reendothelialization contributes to accelerated neointimal hyperplasia after vascular injury. [22] [23] [24] Thus, we examined endothelial regeneration in wire-injured femoral arteries of WT and Clu KO mice. Immunohistochemistry for an endothelial cell specific CD31 antigen revealed that endothelial cell layer lining the luminal wall was markedly restored in wire-injured WT artery ( Figure 6A ). In contrast, CD31-positive staining in the luminal surface was extremely weak in wire-injured artery of Clu KO mice, implying that clusterin deficiency impairs or delays postinjury reendothelialization accompanied by accelerated neointimal hyperplasia.
To further explore the role of clusterin in endothelial cell apoptosis, WST cell viability and caspase-3 assays were performed. Clusterin significantly inhibited TNF-␣-induced apoptosis of human umbilical vein endothelial cells (HUVECs; Figure 6B and 6C). Next, we investigated the effect of clusterin on the expression of endothelial nitric oxide synthase (eNOS), whose decreased expression or activity has been shown to be associated with endothelial dysfunction. 23 TNF-␣ considerably repressed eNOS expression, and this inhibition was restored by Ad-Clu but not by Ad-LacZ ( Figure 6D ). Additionally, Ad-Clu reduced TNF-␣-induced ICAM-1 and VCAM-1 expression in HUVECs, indicating its antiinflammatory property. Collectively, these findings propose that clusterin may facilitate reendothelialization after vascular injury by exerting cytoprotective effects on ECs. Left femoral arteries were obtained from WT and Clu KO mice 21 days after wire injury (hematoxylin and eosin stain; original magnification, ϫ100). B, Neointima formation was presented by the ratio of intimal to medial area (IA/MA). Bars represent the meanϮSEM of each of group (nϭ6); *PϽ0.005 vs noninjured WT, **PϽ0.05 vs wire-injured WT. C, Immunohistochemical staining for clusterin on cross-sections of noninjured and wire-injured femoral arteries of WT and Clu KO mice (original magnification, ϫ400). D, Representative crosssections of noninjured and balloon-injured (BI) rat carotid arteries infused with Ad-GFP or Ad-Clu after BI (hematoxylin and eosin stain; original magnification, ϫ100). Right common carotid arteries were obtained 14 and 28 days after BI.
Discussion
In the present study, we demonstrate that clusterin inhibits VSMC proliferation and migration in vitro and that clusterin deficiency exacerbates and overexpression of clusterin inhibits neointimal hyperplasia induced by vascular injury in vivo. Furthermore, we showed that clusterin has antiapoptotic and antiinflammatory effects on HUVECs, and its deficiency impairs reendothelialization after wire injury in murine femoral arteries in vivo. Therefore, protective role of clusterin against neointimal hyperplasia may be owing to antiproliferative and antimigratory effects on VSMCs and cytoprotective effect on ECs (supplemental Figure VI) .
Clusterin reduced the TNF-␣-stimulated expression of chemokines, cell adhesion molecules, and MMP-9 by repressing NF-B in VSMCs. The TNF-␣/NF-B signaling pathway has also been shown to play an important role in endothelial cell apoptosis and dysfunction by downregulating eNOS and upregulating ICAM-1 and VCAM-1. 27, 28 Therefore, our results suggest that clusterin may regulate function of VSMCs and ECs through repression of TNF-␣/NF-B signaling pathway. Moreover, differential effect of clusterin on VSMCs and ECs may be, at least in part, attributable to the intrinsically distinct effect of TNF-␣ on these cells, namely proliferative and promigratory effect on VSMCs and proapoptotic effect on ECs. 6 -11,26,27 Clusterin also downregulated cyclins D and E, whereas it upregulated p53 and p21, leading to inhibition of pRb phosphorylation and resultant DNA synthesis in VSMCs. The expression and phosphorylation of these proteins were inversely altered in clusterin KO VSMCs. Therefore, our findings suggest that clusterin inhibits VSMC proliferation via induction of G1 cell cycle arrest accompanied by reduced pRb phosphorylation by downregulating cell cycle-promoting factors and upregulating p53-p21 pathway.
However, the molecular mechanism by which clusterin upregulates p53 gene expression awaits further investigations.
As aforementioned, previous studies dealing with VSMC proliferation and migration reported quite conflicting results. 20, 21 Thus, the meaning of clusterin induction during development of neointimal hyperplasia has remained to be defined. To properly address this matter, loss of function study using Clu KO mice would provide more useful information. Here, we demonstrate that clusterin deficiency increases VSMC proliferation in vitro and exacerbates neointimal hyperplasia in vivo. Additionally, re-endothelialization was impaired in wire-injured Clu KO but not WT arteries. However, Ad-Clu did not affect either migration or proliferation of HUVECs (supplemental Figure VII) . Instead, clusterin inhibited TNF-␣-induced apoptosis of HUVECs, whereas it restored the eNOS expression which was repressed by TNF-␣. These results suggest that clusterin might facilitate reendothelialization not through promoting migration and proliferation of neighboring endothelial cells, but through exerting cytoprotective and antiinflammatory effects on endothelial cells adjacent to the injury sites, where TNF-␣ is highly increased. It is also possible that clusterin may promote mobilization or homing of circulating endothelial progenitor cells which contribute to endothelial regeneration, thereby limiting neointimal hyperplasia. 24 Further studies using bone marrow transplantation between WT and Clu KO are necessary to verify this possibility. Collectively, these results suggest that clusterin exerts beneficial effects on the vascular wall at the level of both endothelial cells and VSMCs, resulting in protection against neointimal hyperplasia.
Clusterin is a complex molecule and it is not easy to identify its physiological role in vivo, because there are at least 2 isoforms including secreted (sClu) and nuclear forms (nClu) of clusterin and they show quite different roles in various cancers. 29 However, function of sClu as a tumor promoter or a suppressor is still debated depending on type and stage of cancers, although nClu is generally considered to be proapoptotic. 30 Additionally, a previous study showed that upregulation of nClu and downregulation of sClu by all-trans retinoic acid (RA) mediate proapoptotic and antiproliferative effect of RA on VSMCs, respectively. 26 However, they did not directly demonstrate distinctive role of nClu and sClu on VSMC apoptosis and proliferation through overexpression system either in vitro or in vivo. Hence, the differential effect of sClu and nClu on VSMCs and ECs is still unclear. Here, we demonstrated that conditioned medium containing sClu as well as adenovirus expressing sClu (Ad-Clu) inhibited VSMC proliferation and migration (supplemental Figure VIII) and Ad-Clu has antiapoptotic effect on ECs. Notably, sClu was internalized into VSMCs 2 hours after treatment of the conditioned medium containing sClu (supplemental Figure IX) . Therefore, we suggest that clusterin primarily as a secreted form exerts both antiproliferative effects on VSMCs and prosurvival on ECs. Moreover, Ad-Clu extensively suppressed neointimal thickening in balloon-injured rat carotid arteries. These results demonstrate that sClu inhibits neointimal hyperplasia in vivo. However, further studies are necessary to verify the in vivo and in vitro roles of nClu in neointimal hyperplasia as well as in VSMCs and ECs. From these findings, we propose that clusterin stimulators or small peptides mimicking the sClu action might be used locally or regionally, but not systematically in drug-eluting stents to prevent postangioplasty restenosis, while minimizing the adverse effects, if any, of clusterin such as carcinogenic effect.
In summary, our present study provides new insights into the role of clusterin during vascular injury. Clusterin induction may be a necessary and compensatory response to prevent neointimal hyperplasia in acute and chronic vascular injuries including balloon angioplasty and atherosclerosis.
